SpyGlass Pharma, Inc.
No SEC Form 4 filings for $SGP in the last 30 days.
SpyGlass Pharma, Inc. (SGP) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-8kprx080626.htm EX-99.1 Document Exhibit 99.1 SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates • Enrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL Syste
Manila Electric Co. (Meralco) said it will join discussions on proposed amendments to the Electric Power Industry Reform Act (EPIRA) that could remove system loss charges from electricity bills. Meralco warned reforms should preserve distribution utility investment capacity. System loss is about 5% of bills in Meralco’s area. Meralco shares fell 4.66% to P562; SGP fell 0.36% to P28.
Australia’s ASX 200 (XJO) closed at 8,947.8, up 0.61%, a six-week high, after RBA Governor Michele Bullock signaled housing and labour markets have softened more than expected, easing August rate hike fears. The 10-year yield fell 5.2 bps. Consumer, tech and financials rose; gold, copper and lithium stocks fell.
Over the past 7 days, alphai's AI scored 1 news story mentioning SGP (SpyGlass Pharma, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent SGP coverage spans financial news, macro economy and earnings.
The filing provides fresh operational timelines and cash runway, which can shift probability-weighted FDA approval and near-term financing risk.
Even without charging consumers for transmission system loss, SGP is exposed to market-wide regulatory uncertainty around system loss charge treatment.
SGP’s move is consistent with real estate re-rating on lower yields.
New general counsel appointment can affect governance, deal execution, and legal risk management, but no direct operational or financial guidance is provided.
Policy incentives plus demand for new builds are presented as supportive for Stockland’s lot and home settlements and margins.
alphai scores every news story that mentions SGP with an AI model for sentiment and relevance, and aggregates insider trades from SpyGlass Pharma, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
SpyGlass Pharma, Inc. (SGP) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-8kprx080626.htm EX-99.1 Document Exhibit 99.1 SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates • Enrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL Syste
6 min readManila Electric Co. (Meralco) said it will join discussions on proposed amendments to the Electric Power Industry Reform Act (EPIRA) that could remove system loss charges from electricity bills. Meralco warned reforms should preserve distribution utility investment capacity. System loss is about 5% of bills in Meralco’s area. Meralco shares fell 4.66% to P562; SGP fell 0.36% to P28.
4 min readAustralia’s ASX 200 (XJO) closed at 8,947.8, up 0.61%, a six-week high, after RBA Governor Michele Bullock signaled housing and labour markets have softened more than expected, easing August rate hike fears. The 10-year yield fell 5.2 bps. Consumer, tech and financials rose; gold, copper and lithium stocks fell.
7 min readSpyGlass Pharma Inc. appointed Shannon Treviño as general counsel, the company said. Treviño previously served as general counsel and corporate secretary at Inari Medical, acquired by Stryker for $4.9 billion, and held earlier legal and academic roles. SpyGlass CEO Patrick Mooney said she will support the company’s growth. Shares rose 2.7% to $18.93.
2 min readMaster Builders Australia forecasts Australia will miss its target of 1.2 million new homes by July 2029, with a shortfall rising to 180,200 homes (from 160,000 earlier). It also says 180,500 homes started in 2024-25, about 60,000 below the Accord’s 240,000 goal. The article highlights ASX names James Hardie, Stockland and Mirvac as potential beneficiaries.
4 min readSpyGlass Pharma (Nasdaq: SGP) announced its executive management will participate in three upcoming investor conferences focused on healthcare and ophthalmology in May and June 2026. These events include the Stifel 2026 Virtual Ophthalmology Forum, the Jefferies Global Healthcare Conference, and the Goldman Sachs 47th Annual Global Healthcare Conference. The company will deliver corporate presentations or engage in fireside chats, with webcasts and replays available on its investor relations website.
2 min readSpyGlass Pharma Inc. has secured a new add-on Category III CPT Code for its intraocular lens (IOL) platform, which delivers glaucoma medication for up to three years. The Aliso Viejo-based company is currently in Phase 3 trials and aims for FDA submission by 2028 and commercial launch in 2029. This new billing code is expected to support the commercial model for their novel technology combining glaucoma and cataract treatment.
3 min readStifel analyst James Condulis initiated coverage on Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) with a Buy rating and a $21 price target. This article also highlights three other significant analyst initiations for Tuesday, including Goldman Sachs on Once Upon A Farm PBC (NYSE: OFRM), Morgan Stanley on Agomab Therapeutics NV (NASDAQ: AGMB), and Stifel on SpyGlass Pharma, Inc. (NASDAQ: SGP), all with bullish ratings and specific price targets.
4 min read
